ICYMI, some of this week’s featured content includes new treatment guidelines for AK, health care impacts on gender and sexual minority patients, upadacitinib for atopic dermatitis, plus more
Join us in an upcoming webinar sponsored by Aerolase that provides the latest insight on how to grow your practice and profits beyond the COVID-19 pandemic.
This week’s edition of The Mainstream Patient features stories about microcurrent facials, the psoriasis treatment journey, melanoma survivor stories, plus more.
New regulations, latest absorption data, and updates on environmental and health impacts are shaping the world of photoprotection.
The Journal of the American Academy of Dermatology has published new recommendations for the treatment of actinic keratosis (AK).
Creating an effective treatment regimen for adult females with acne requires a holistic approach that considers the physical and psychological aspects of the world’s most common skin condition.
In this video interview, Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/GSM Expert Resource Group, dives into the impacts health care policies such as the Affordable Care Act and Medicaid expansion have on gender and sexual minority patients.
The COVID-19 pandemic had forced vitiligo patients to delay treatments; however, not much is known about the effects of delaying on disease course.
More than 90% of respondents to a recent survey expressed concern about acne’s effect on their adolescent’s mental health and social life.
Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.
Emma Guttman-Yassky, MD, sits down with Dermatology Times® to discuss recently published results of a phase 3 study evaluating upadacitinib (Rinvoq, AbbVie) as a potential treatment of atopic dermatitis.
Study results reveal that nanosecond pulsed electric field therapy alters the C. acnes biofilm to enable better treatment penetration.
John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.